Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
复制标题
DOI：
10.1073/pnas.0402653101
复制
发表时间：
2004-06-08
影响因子：
11.1
通讯作者：
Martin, R
中科院分区：
文献类型：
--
作者：
Bielekova, B;Richert, N;Martin, R
为标准治疗失败的MS患者确定有效的治疗组合是一个重要的目标。我们报告了一项针对CD 25的人源化单克隆抗体（daclizumab）在10例对IFN-β治疗反应不完全、脑炎症和临床疾病活动度高的多发性硬化症患者中进行的II期开放标签基线至治疗试验的结果。Daclizumab的耐受性非常好，导致新的对比度增强病变减少78%，并在几个临床结局指标中显着改善。
Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.